Blood pressure response to mineralocorticoid receptor antagonists or aldosterone synthase inhibitors according to baseline renin levels.

IF 2.7 4区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Human Hypertension Pub Date : 2025-05-03 DOI:10.1038/s41371-025-01021-9

Ana Rita Leite, António Angélico-Gonçalves, Adelino Leite-Moreira, João Sérgio Neves, João Pedro Ferreira

引用次数: 0

Abstract

Plasma renin is a surrogate marker of sodium retention in hypertension, and its levels are suppressed in conditions of heightened aldosterone production. We performed a random-effects meta-analysis of randomized clinical trials focusing on the impact of mineralocorticoid receptor antagonists (MRA) and aldosterone synthase inhibitors (ASi) on blood pressure according to baseline renin levels. We included four randomized clinical trials, and we found that the response to MRA or ASi was independent of baseline plasma renin levels.

查看原文本刊更多论文

根据基线肾素水平，血压对矿化皮质激素受体拮抗剂或醛固酮合成酶抑制剂的反应。

血浆肾素是高血压患者钠潴留的替代标志物，其水平在醛固酮产生升高的情况下受到抑制。我们对随机临床试验进行了随机效应荟萃分析，重点关注矿皮质激素受体拮抗剂（MRA）和醛固酮合成酶抑制剂（ASi）根据基线肾素水平对血压的影响。我们纳入了四项随机临床试验，发现对MRA或ASi的反应与基线血浆肾素水平无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Human Hypertension 医学-外周血管病

CiteScore

5.20

自引率

3.70%

发文量

126

审稿时长

6-12 weeks

期刊介绍： Journal of Human Hypertension is published monthly and is of interest to health care professionals who deal with hypertension (specialists, internists, primary care physicians) and public health workers. We believe that our patients benefit from robust scientific data that are based on well conducted clinical trials. We also believe that basic sciences are the foundations on which we build our knowledge of clinical conditions and their management. Towards this end, although we are primarily a clinical based journal, we also welcome suitable basic sciences studies that promote our understanding of human hypertension. The journal aims to perform the dual role of increasing knowledge in the field of high blood pressure as well as improving the standard of care of patients. The editors will consider for publication all suitable papers dealing directly or indirectly with clinical aspects of hypertension, including but not limited to epidemiology, pathophysiology, therapeutics and basic sciences involving human subjects or tissues. We also consider papers from all specialties such as ophthalmology, cardiology, nephrology, obstetrics and stroke medicine that deal with the various aspects of hypertension and its complications.